인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
Neonatal myocardial infarction is a rare and often life-threatening condition, particularly in preterm neonates, with nonspecific clinical presentations that complicate diagnosis. While diagnosis relies on ECG changes, elevated cardiac markers, and echocardiographic abnormalities, management guidelines and validated biomarker cut-offs for neonates are lacking. Conventional inotropic support is often necessary, but its efficacy in immature myocardium can be limited. Levosimendan, a calcium sensitizer with inotropic, lusitropic, and vasodilatory effects, offers potential advantages by improving contractility without increasing myocardial oxygen consumption, but evidence in neonates, especially preterm infants, remains scarce. We report the case of an extremely preterm neonate (26 + 6 weeks gestation) who developed severe myocardial ischemic injury and refractory cardiogenic shock following perinatal hypoxic-ischemic insult. Despite aggressive resuscitation and conventional inotropic support with Dobutamine, Noradrenaline, and Milrinone, the infant’s condition remained critical with persistent severe left ventricular dysfunction. Given the lack of response to conventional therapy, off-label levosimendan was initiated. Within 48 h, significant clinical and echocardiographic improvement was observed, including shock resolution and recovery of left ventricular ejection fraction. This case highlights the successful use of Levosimendan in a preterm neonate with severe myocardial ischemic injury and refractory cardiogenic shock, where conventional inotropes failed to improve cardiac function. Levosimendan’s unique mechanism of action, which enhances contractility without increasing myocardial oxygen demand, proved beneficial in the context of an immature myocardium. While further studies are needed to standardize its application and establish clear guidelines, this case suggests that Levosimendan may be a valuable therapeutic option for acute heart failure in preterm neonates, particularly in cases unresponsive to traditional treatments.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
